MiNK Therapeutics, Inc. Rings the Opening Bell in Celebration of its IPO

ABOUT THIS EVENT

MiNK Therapeutics, Inc. (Nasdaq: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, visits the Nasdaq MarketSite in Times Square.

In honor of the occasion, Jennifer Buell, Ph.D., Chief Executive Officer, rings the Opening Bell.

Nasdaq Originals Exclusive insights on the forces shaping the convergence of technology, business and sports. Explore